1. participation in any other clinical trial with antiviral activity against covid-19 2. breastfeeding women 3. known hypersensitivity to atovaquone or formulation excipient 4. active treatment with rifampin 5. hiv patients with aids requiring treatment for pneumocystis jirovecii or toxoplasma gondii 6. not expected to survive for 72 hours. 7) \>14 days from symptom onset

1. participation in any other clinical trial with antiviral activity against covid-19 2. breastfeeding women 3. known hypersensitivity to atovaquone or formulation excipient 4. active treatment with rifampin 5. hiv patients with aids requiring treatment for pneumocystis jirovecii or toxoplasma gondii 6. not expected to survive for 72 hours. 7) \>14 days from symptom onset

participation in any other clinical trial with antiviral activity against covid-19 breastfeeding women known hypersensitivity to atovaquone or formulation excipient active treatment with rifampin hiv patients with aids requiring treatment for pneumocystis jirovecii or toxoplasma gondii not expected to survive for 72 hours. 7) >14 days from symptom onset

participation in any other clinical trial with antiviral activity against covid-19 breastfeeding women known hypersensitivity to atovaquone or formulation excipient active treatment with rifampin hiv patients with aids requiring treatment for pneumocystis jirovecii or toxoplasma gondii not expected to survive for 72 hours. 7) >14 days from symptom onset

1. participation in any other clinical trial with antiviral activity against covid-19 2. breastfeeding women 3. known hypersensitivity to atovaquone or formulation excipient 4. active treatment with rifampin 5. hiv patients with aids requiring treatment for pneumocystis jirovecii or toxoplasma gondii 6. not expected to survive for 72 hours. 7) >14 days from symptom onset

1. participation in any other clinical trial with antiviral activity against covid-19 2. breastfeeding women 3. known hypersensitivity to atovaquone or formulation excipient 4. active treatment with rifampin 5. hiv patients with aids requiring treatment for pneumocystis jirovecii or toxoplasma gondii 6. not expected to survive for 72 hours. 7) >14 days from symptom onset